Show simple item record

dc.contributor.authorRiddle, MC
dc.contributor.authorPhilipson, LH
dc.contributor.authorRich, SS
dc.contributor.authorCarlsson, A
dc.contributor.authorFranks, PW
dc.contributor.authorGreeley, SAW
dc.contributor.authorNolan, JJ
dc.contributor.authorPearson, ER
dc.contributor.authorZeitler, PS
dc.contributor.authorHattersley, AT
dc.date.accessioned2021-03-08T13:47:39Z
dc.date.issued2020-11-20
dc.description.abstractIndividualization of therapy based on a person’s specific type of diabetes is one key element of a “precision medicine” approach to diabetes care. However, applying such an approach remains difficult because of barriers such as disease heterogeneity, difficulties in accurately diagnosing different types of diabetes, multiple genetic influences, incomplete understanding of pathophysiology, limitations of current therapies, and environmental, social, and psychological factors. Monogenic diabetes, for which single gene mutations are causal, is the category most suited to a precision approach. The pathophysiological mechanisms of monogenic diabetes are understood better than those of any other form of diabetes. Thus, this category offers the advantage of accurate diagnosis of nonoverlapping etiological subgroups for which specific interventions can be applied. Although representing a small proportion of all diabetes cases, monogenic forms present an opportunity to demonstrate the feasibility of precision medicine strategies. In June 2019, the editors of Diabetes Care convened a panel of experts to discuss this opportunity. This article summarizes the major themes that arose at that forum. It presents an overview of the common causes of monogenic diabetes, describes some challenges in identifying and treating these disorders, and reports experience with various approaches to screening, diagnosis, and management. This article complements a larger American Diabetes Association effort supporting implementation of precision medicine for monogenic diabetes, which could serve as a platform for a broader initiative to apply more precise tactics to treating the more common forms of diabetes.en_GB
dc.identifier.citationVol. 43 (12), pp. 3117 - 3128en_GB
dc.identifier.doi10.2337/dci20-0065
dc.identifier.urihttp://hdl.handle.net/10871/125056
dc.language.isoenen_GB
dc.publisherAmerican Diabetes Associationen_GB
dc.rights© 2020 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at https://www.diabetesjournals.org/content/license.en_GB
dc.titleMonogenic Diabetes: From Genetic Insights to Population-Based Precision in Care. Reflections From a Diabetes Care Editors' Expert Forumen_GB
dc.typeArticleen_GB
dc.date.available2021-03-08T13:47:39Z
dc.identifier.issn0149-5992
dc.descriptionThis is the author accepted manuscript. The final version is available from the American Diabetes Association via the DOI in this recorden_GB
dc.identifier.journalDiabetes Careen_GB
dc.rights.urihttp://www.rioxx.net/licenses/all-rights-reserveden_GB
dcterms.dateAccepted2020-09-14
rioxxterms.versionAMen_GB
rioxxterms.licenseref.startdate2020-11-20
rioxxterms.typeJournal Article/Reviewen_GB
refterms.dateFCD2021-03-08T13:42:45Z
refterms.versionFCDAM
refterms.dateFOA2021-03-08T13:47:43Z
refterms.panelAen_GB


Files in this item

This item appears in the following Collection(s)

Show simple item record